Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,786
archived clinical trials in
Dermatology

Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands
Status: Enrolling
Updated:  7/8/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Hypertrophic Actinic Keratoses
An Investigator-Initiated Study to Assess the Safety and Efficacy of Ingenol Mebutate 0.05% Gel When Used After Cryotherapy in the Treatment of Hypertrophic Actinic Keratoses (AK) on Dorsal Hands
Status: Enrolling
Updated: 7/8/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Microdermabrasion for Acne
Microdermabrasion for Acne Vulgaris
Status: Enrolling
Updated:  7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Microdermabrasion for Acne
Microdermabrasion for Acne Vulgaris
Status: Enrolling
Updated: 7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study
Status: Enrolling
Updated:  7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
UVA1 Light for Treatment of Scleroderma and Similar Conditions
The Effectiveness Of UVA1 Irradiation In The Treatment Of Skin Conditions With Altered Dermal Matrix: A Controlled, Cross-Over Study
Status: Enrolling
Updated: 7/8/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment
An Investigator-Initiated Study to Assess the Safety and Efficacy of Sinecatechins 15% Ointment When Used in Conjunction With Cryotherapy in the Treatment of External Genital Warts
Status: Enrolling
Updated:  7/8/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Treatment of External Genital Warts With Cryotherapy and Sinecatechins 15% Ointment
An Investigator-Initiated Study to Assess the Safety and Efficacy of Sinecatechins 15% Ointment When Used in Conjunction With Cryotherapy in the Treatment of External Genital Warts
Status: Enrolling
Updated: 7/8/2015
Icahn School of Medicine at Mount Sinai
mi
from
New York, NY
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Center for Dermatology Clinical Research
mi
from
Fremont, CA
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
UCSD Dermatology
mi
from
San Diego, CA
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
UCSD Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
The Center for Clinical and Cosmetic Research
mi
from
Aventura, FL
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
The Center for Clinical and Cosmetic Research
mi
from
Aventura, FL
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Moore Clinical Research Inc.
mi
from
Brandon, FL
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Moore Clinical Research Inc.
mi
from
Brandon, FL
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Spencer Clinical Services
mi
from
St. Petersburg, FL
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Spencer Clinical Services
mi
from
St. Petersburg, FL
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Altman Dermatology Associates
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Shideler Clinical Research Center
mi
from
Carmel, IN
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Shideler Clinical Research Center
mi
from
Carmel, IN
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
The Indiana Clinical Trials Center, PC
mi
from
Plainfield, IN
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Minnesota Clinical Study Center
mi
from
Fridley, MN
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Minnesota Clinical Study Center
mi
from
Fridley, MN
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Oregon Dermatology & Research Center
mi
from
Portland, OR
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Oregon Dermatology & Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
J&S Studies
mi
from
College Station, TX
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
J&S Studies
mi
from
College Station, TX
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Suzanne Bruce and associates P.A. The Center for skin Research
mi
from
Houston, TX
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Suzanne Bruce and associates P.A. The Center for skin Research
mi
from
Houston, TX
Click here to add this to my saved trials
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated:  7/14/2015
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Twelve Month Follow-Up of CP0108
Twelve Month Follow-Up Evaluation of Subjects Participating in DUSA-CP0108 (A Phase 3 Study of Photodynamic Therapy With Levulan Kerastick Topical Solution + Blue Light Versus Topical Solution Vehicle + Blue Light for the Treatment of Actinic Keratoses on the Upper Extremities)
Status: Enrolling
Updated: 7/14/2015
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases
Status: Enrolling
Updated:  7/20/2015
Duke University Health System
mi
from
Durham, NC
Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases
Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases
Status: Enrolling
Updated: 7/20/2015
Duke University Health System
mi
from
Durham, NC
Click here to add this to my saved trials
Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses
Photodynamic Therapy With Levulan® Topical Solution And Blue Light +/- Topical Retinoid Pre-Treatment In The Treatment Of Dorsal Hand/Forearm Actinic Keratoses
Status: Enrolling
Updated:  7/21/2015
Roger Stewart MD PA
mi
from
Fort Lauderdale, FL
Photodynamic Therapy With Levulan® +/- Topical Retinoid Pre-Treatment In The Treatment Of Actinic Keratoses
Photodynamic Therapy With Levulan® Topical Solution And Blue Light +/- Topical Retinoid Pre-Treatment In The Treatment Of Dorsal Hand/Forearm Actinic Keratoses
Status: Enrolling
Updated: 7/21/2015
Roger Stewart MD PA
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
National Jewish Health
mi
from
Denver, CO
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
National Jewish Health
mi
from
Denver, CO
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
University of Rochester
mi
from
Rochester, NY
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
University of Rochester
mi
from
Rochester, NY
Click here to add this to my saved trials
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated:  7/23/2015
Oregon Health and Science University
mi
from
Portland, OR
ADRN Barrier/Immunoprofiling Exploratory Pilot Study
ADRN Barrier/Immunoprofiling Exploratory Pilot Study (ADRN-04)
Status: Enrolling
Updated: 7/23/2015
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
UVA1 Light for Scleroderma and Similar Conditions
The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Status: Enrolling
Updated:  7/24/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
UVA1 Light for Scleroderma and Similar Conditions
The Effectiveness of UVA1 Irradiation in the Treatment of Skin Conditions With Altered Dermal Matrix: An Open Pilot Study
Status: Enrolling
Updated: 7/24/2015
University of Michigan Department of Dermatology
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study for the RevLite Laser System for Facial Solar Lentigines
Study for the RevLite Laser System for Facial Solar Lentigines
Status: Enrolling
Updated:  7/29/2015
Sadick Research Group
mi
from
New York, NY
Study for the RevLite Laser System for Facial Solar Lentigines
Study for the RevLite Laser System for Facial Solar Lentigines
Status: Enrolling
Updated: 7/29/2015
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Stanford University Hospitals and Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Univ of North Carolina
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
mi
from
Seattle, WA
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Weill-Cornell Medical College
mi
from
New York, NY
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Weill-Cornell Medical College
mi
from
New York, NY
Click here to add this to my saved trials
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated:  8/10/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Imatinib and Rituximab in Treating Cutaneous Sclerosis in Patients With Chronic Graft-Versus-Host Disease
A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis After Allogeneic Hematopoietic Cell Transplantation
Status: Enrolling
Updated: 8/10/2015
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Birmingham (2 locations), AL
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Birmingham (2 locations), AL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Mobile, AL
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Tucson, AZ
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Bakersfield, CA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Bakersfield, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
San Diego (2 locations), CA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
San Diego (2 locations), CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Santa Monica, CA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Jacksonville (2 locations), FL
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Jacksonville (2 locations), FL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Ormond Beach, FL
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Skokie, IL
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Skokie, IL
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
New Orleans, LA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Andover, MA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Andover, MA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Boston (2 locations), MA
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Boston (2 locations), MA
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
Troy, MI
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
Troy, MI
Click here to add this to my saved trials
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated:  8/10/2015
Clinical Research Facility
mi
from
St. Louis, MO
Study of Dupilumab (REGN668/SAR231893) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study Investigating the Efficacy, Safety, Pharmacokinetic and Biomarker Profiles of Dupilumab (REGN668) Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis
Status: Enrolling
Updated: 8/10/2015
Clinical Research Facility
mi
from
St. Louis, MO
Click here to add this to my saved trials